Michiel de Haan
Founder and Managing Partner @ Aescap Venture
Laren, The Netherlands
Michiel de Haan is a Series G investor at Aescap Venture in Laren focused on Chemical and Biotechnology. Michiel de Haan is the current Founder and Managing Partner of Aescap Venture. He previously worked at Avantium as a Advisory Board and Past Chairman. Michiel de Haan attended Erasmus University Rotterdam.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Michiel de Haan invests in
Stages Michiel de Haan invests in
Countries Michiel de Haan invests in
Investment Focus
Industry
- Chemical 1 (33%)
- Biotechnology 1 (33%)
- Pharmaceutical 1 (33%)
- Renewable Energy 1 (33%)
Stage
- Series G 1 (33%)
- Funding Round 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Avantium
|
Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands.Avantium's proprietary high-throughput technology enables a faster and morecost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development.Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields:new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent.Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business.Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations. | $42.1M / Series G / May 22, 2014 | |
|
Avantium
|
Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands.Avantium's proprietary high-throughput technology enables a faster and morecost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development.Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields:new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent.Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business.Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations. | $48.2M / Jun 09, 2011 | |
|
Avantium
|
Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands.Avantium's proprietary high-throughput technology enables a faster and morecost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development.Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields:new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent.Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business.Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations. | $18M / Oct 29, 2008 |
Co-Investors
Aster
2 deals together
Capricorn Partners
2 deals together
De Hoge Dennen Capital
2 deals together
ALPLA
1 deal together
DANONE
1 deal together
ING Corporate Investments
1 deal together
About Aescap Venture
Aescap Venture is an Amsterdam-based investment company that pursues investments in biotech companies in Europe and the U.S.
Aescap Venture Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Michiel de Haan
Founder and Managing Partner
|
|||
Wolfgang Noeldeke
Financial officer
|
|||
Patrick Krol
managing partner
|
|||
|
Rainer Christine
Partner
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Michiel de Haan invest in?
Michiel de Haan invests primarily in Chemical, Biotechnology and Pharmaceutical startups, most often at Series G and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Michiel de Haan last invest?
The most recent investment recorded for Michiel de Haan closed in May 2014. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
